- Home
- ZYME vs GLUE Comparison
ZYME vs GLUE Comparison
Compare ZYME & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZYME | GLUE |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZYME | GLUE |
|---|---|---|
| Price | $22.81 | $22.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $38.90 | $32.00 |
| AVG Volume (30 Days) | 531.8K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $105,965,000.00 | ★ $123,672,000.00 |
| Revenue This Year | $183.10 | N/A |
| Revenue Next Year | N/A | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | 38.87 | ★ 63.54 |
| 52 Week Low | $11.86 | $4.12 |
| 52 Week High | $29.75 | $25.77 |
Technical Indicators
Market Signals| Indicator | ZYME | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 52.14 |
| Support Level | $22.20 | $17.35 |
| Resistance Level | $23.66 | $25.45 |
| Average True Range (ATR) | 0.92 | 1.54 |
| MACD | -0.30 | -0.25 |
| Stochastic Oscillator | 1.07 | 43.57 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).